Detail akcie BioAlliance online

Business Summary: Valerio Therapeutics SA formerly Onxeo SA is a France-based clinical-stage biotechnology company. The company targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). It aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. It also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Valerio Therapeutics SA revenues increased 44% to EUR2.6M. Net loss applicable to common stockholders decreased 80% to EUR4.9M. Revenues reflect France segment increase from EUR0K to EUR701K, Rest of the World segment increase of 4% to EUR1.9M. Lower net loss reflects Licensing Agreement segment loss decrease of 82% to EUR4.3M.